Summit Therapeutics Inc. Income Tax Expense Continuing Operations
Summit Therapeutics Inc. (SMMT) reported Income Tax Expense Continuing Operations of -GBP 1.04 million for the 3-month period ending 2020-03-31, per its 6-K filed 2020-06-02.
Discontinued › Expense Statement › Income Tax
ifrs-full:IncomeTaxExpenseContinuingOperations · last filed 2020-06-02
- Summit Therapeutics Inc. income tax expense continuing operations for the quarter ending 2020-03-31 was -1.04M GBP.
- Summit Therapeutics Inc. income tax expense continuing operations for the quarter ending 2019-10-31 was -727.00K GBP.
- Summit Therapeutics Inc. income tax expense continuing operations for the quarter ending 2019-07-31 was -1.06M GBP, a 316.29% decline year-over-year.
- Summit Therapeutics Inc. income tax expense continuing operations for the quarter ending 2019-04-30 was -842.00K GBP.
| Period end | Income Tax Expense Continuing Operations 3 month | Income Tax Expense Continuing Operations 6 month | Income Tax Expense Continuing Operations 9 month | Income Tax Expense Continuing Operations 11 month | Income Tax Expense Continuing Operations 12 month | Income Tax Expense Continuing Operations 12 month as first filed |
|---|---|---|---|---|---|---|
| 2020-03-31 | -1.04M GBP 6-K · filed 2020-06-02 | |||||
| 2019-12-31 | -3.52M GBP 20-F · filed 2020-04-30 | |||||
| 2019-10-31 | -727.00K GBP 6-K · filed 2019-12-17 | -1.79M GBP derived: sum of 2 quarters · filed 2019-12-17 | -2.63M GBP 6-K · filed 2019-12-17 | |||
| 2019-07-31 | -1.06M GBP 6-K · filed 2019-10-11 | -1.90M GBP 6-K · filed 2019-10-11 | ||||
| 2019-04-30 | -842.00K GBP 6-K · filed 2019-06-12 | |||||
| 2019-03-31 | -831.00K GBP 6-K · filed 2020-06-02 | |||||
| 2019-01-31 | -766.00K GBP derived: 20-F 12 month − 6-K 9 month · filed 2020-04-30 | -2.04M GBP derived: sum of 2 quarters · filed 2020-04-30 | -1.55M GBP derived: sum of 3 quarters · filed 2020-04-30 | -2.50M GBP 20-F · filed 2020-04-30 | ||
| 2018-10-31 | -1.27M GBP 6-K · filed 2019-12-17 | -784.00K GBP derived: sum of 2 quarters · filed 2019-12-17 | -1.73M GBP 6-K · filed 2019-12-17 | -1.53M GBP derived: sum of 4 quarters · filed 2020-04-30 | ||
| 2018-07-31 | 491.00K GBP 6-K · filed 2019-10-11 | -455.00K GBP 6-K · filed 2019-10-11 | -258.00K GBP derived: sum of 3 quarters · filed 2020-04-30 | -1.73M GBP derived: sum of 4 quarters · filed 2020-04-30 | ||
| 2018-04-30 | -946.00K GBP 6-K · filed 2019-06-12 | -749.00K GBP derived: sum of 2 quarters · filed 2020-04-30 | -2.22M GBP derived: sum of 3 quarters · filed 2020-04-30 | -3.50M GBP derived: sum of 4 quarters · filed 2020-04-30 | ||
| 2018-01-31 | 197.00K GBP derived: 20-F 12 month − 6-K 9 month · filed 2020-04-30 | -1.28M GBP derived: sum of 2 quarters · filed 2020-04-30 | -2.56M GBP derived: sum of 3 quarters · filed 2020-04-30 | -3.76M GBP 20-F · filed 2020-04-30 | 3.76M GBP 20-F · filed 2018-04-13 | |
| 2017-10-31 | -1.47M GBP 6-K · filed 2018-12-11 | -2.76M GBP derived: sum of 2 quarters · filed 2018-12-11 | -3.96M GBP 6-K · filed 2018-12-11 | |||
| 2017-07-31 | -1.28M GBP 6-K · filed 2018-09-20 | -2.49M GBP 6-K · filed 2018-09-20 | ||||
| 2017-04-30 | -1.20M GBP 6-K · filed 2018-06-05 | |||||
| 2017-01-31 | -4.34M GBP 20-F · filed 2019-03-29 | 4.34M GBP 20-F · filed 2018-04-13 | ||||
| 2016-01-31 | 3.06M GBP 20-F · filed 2018-04-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |